| Published Application/Species/Sample/Dilution | Reference |
|---|
- flow cytometry; mouse; loading ...; fig s4b
| Tang T, Huang X, Zhang G, Lu M, Hong Z, Wang M, et al. Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis. J Immunother Cancer. 2022;10: pubmed publisher |
- flow cytometry; mouse; loading ...; fig 5k
| Lu C, Liu Z, Klement J, Yang D, Merting A, Poschel D, et al. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape. J Immunother Cancer. 2021;9: pubmed publisher |
- flow cytometry; mouse; 1:200; loading ...
| Van De Velde L, Allen E, Crawford J, Wilson T, Guy C, Russier M, et al. Neuroblastoma Formation Requires Unconventional CD4 T Cells and Arginase-1-Dependent Myeloid Cells. Cancer Res. 2021;81:5047-5059 pubmed publisher |
- flow cytometry; mouse; loading ...; fig 5f
| Lauret Marie Joseph E, Kirilovsky A, Lecoester B, El Sissy C, Boullerot L, Rangan L, et al. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy. J Immunother Cancer. 2021;9: pubmed publisher |
- flow cytometry; mouse; fig 4b
| Kasuga A, Semba T, Sato R, Nobusue H, Sugihara E, Takaishi H, et al. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice. Cancer Sci. 2021;112:1822-1838 pubmed publisher |
- flow cytometry; mouse; loading ...; fig 3d
| Yan D, Wang J, Sun H, Zamani A, Zhang H, Chen W, et al. TIPE2 specifies the functional polarization of myeloid-derived suppressor cells during tumorigenesis. J Exp Med. 2020;217: pubmed publisher |
- flow cytometry; mouse; loading ...; fig 2h
| Findlay E, Currie A, Zhang A, Ovciarikova J, Young L, Stevens H, et al. Exposure to the antimicrobial peptide LL-37 produces dendritic cells optimized for immunotherapy. Oncoimmunology. 2019;8:1608106 pubmed publisher |
- flow cytometry; mouse; 1:200; loading ...; fig 4h
| Sang A, Danhorn T, Peterson J, Rankin A, O Connor B, Leach S, et al. Innate and adaptive signals enhance differentiation and expansion of dual-antibody autoreactive B cells in lupus. Nat Commun. 2018;9:3973 pubmed publisher |
- flow cytometry; mouse; 1:200; loading ...; fig s1a
| Tang H, Liang Y, Anders R, Taube J, Qiu X, Mulgaonkar A, et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Invest. 2018;128:580-588 pubmed publisher |
- flow cytometry; mouse; loading ...; fig 1d
| Lynch A, Hawk W, Nylen E, Ober S, Autin P, Barber A. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma. Immunology. 2017;152:472-483 pubmed publisher |
- flow cytometry; mouse; 1:300; loading ...; fig 1a, 2b
| Liu Z, Ravindranathan R, Kalinski P, Guo Z, Bartlett D. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun. 2017;8:14754 pubmed publisher |
- flow cytometry; mouse; fig 4a
| Azpilikueta A, Agorreta J, Labiano S, Pérez Gracia J, Sánchez Paulete A, Aznar M, et al. Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies. J Thorac Oncol. 2016;11:524-36 pubmed publisher |
- flow cytometry; mouse; loading ...; fig 5a
| Ngiow S, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, et al. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Res. 2015;75:3800-11 pubmed publisher |
| Tu J, Xu H, Ma L, Li C, Qin W, Chen X, et al. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells. Theranostics. 2022;12:747-766 pubmed publisher |
| Guo L, Li N, Yang Z, Li H, Zheng H, Yang J, et al. Role of CXCL5 in Regulating Chemotaxis of Innate and Adaptive Leukocytes in Infected Lungs Upon Pulmonary Influenza Infection. Front Immunol. 2021;12:785457 pubmed publisher |
| Zhang X, SABIO E, Krishna C, Ma X, Wang J, Jiang H, et al. Qa-1b Modulates Resistance to Anti-PD-1 Immune Checkpoint Blockade in Tumors with Defects in Antigen Processing. Mol Cancer Res. 2021;19:1076-1084 pubmed publisher |
| Rashid M, Borin T, Ara R, Piranlioglu R, Achyut B, Korkaya H, et al. Critical immunosuppressive effect of MDSC‑derived exosomes in the tumor microenvironment. Oncol Rep. 2021;45:1171-1181 pubmed publisher |
| Ren J, Xu M, Chen J, Ding J, Wang P, Huo L, et al. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a 177Lu-labeled αPD-L1 antibody. Theranostics. 2021;11:304-315 pubmed publisher |
| Holokai L, Chakrabarti J, Lundy J, Croagh D, Adhikary P, Richards S, et al. Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2020;12: pubmed publisher |
| Zhang Y, Dong X, Bai L, Shang X, Zeng Y. MUC1-induced immunosuppression in colon cancer can be reversed by blocking the PD1/PDL1 signaling pathway. Oncol Lett. 2020;20:317 pubmed publisher |
| Lin R, Zhang Y, Pradhan K, Li L. TICAM2-related pathway mediates neutrophil exhaustion. Sci Rep. 2020;10:14397 pubmed publisher |
| Lerbs T, Cui L, King M, Chai T, Muscat C, Chung L, et al. CD47 prevents the elimination of diseased fibroblasts in scleroderma. JCI Insight. 2020;5: pubmed publisher |
| Khan K, Ponce de León J, Benguigui M, Xu P, Chow A, Cruz Munoz W, et al. Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer. NPJ Breast Cancer. 2020;6:29 pubmed publisher |
| Vardhana S, Hwee M, Berisa M, Wells D, Yost K, King B, et al. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nat Immunol. 2020;: pubmed publisher |
| Lovisa S, Fletcher Sananikone E, Sugimoto H, Hensel J, Lahiri S, Hertig A, et al. Endothelial-to-mesenchymal transition compromises vascular integrity to induce Myc-mediated metabolic reprogramming in kidney fibrosis. Sci Signal. 2020;13: pubmed publisher |
| Fu Y, Liu C, Kobayashi D, Johanns T, Bowman Kirigin J, Schaettler M, et al. GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors. Sci Rep. 2020;10:9027 pubmed publisher |
| Davidson S, Efremova M, Riedel A, Mahata B, Pramanik J, Huuhtanen J, et al. Single-Cell RNA Sequencing Reveals a Dynamic Stromal Niche That Supports Tumor Growth. Cell Rep. 2020;31:107628 pubmed publisher |
| Pein M, Insua Rodríguez J, Hongu T, Riedel A, Meier J, Wiedmann L, et al. Metastasis-initiating cells induce and exploit a fibroblast niche to fuel malignant colonization of the lungs. Nat Commun. 2020;11:1494 pubmed publisher |
| Williams J, Li S, Higgs E, Cabanov A, Wang X, Huang H, et al. Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells. Nat Commun. 2020;11:602 pubmed publisher |
| Chen L, Yang Q, Li Y, Yang L, Liu J, Li H, et al. Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma. Cancer Immunol Res. 2020;8:179-191 pubmed publisher |
| Zhang C, Yue C, Herrmann A, Song J, Egelston C, Wang T, et al. STAT3 Activation-Induced Fatty Acid Oxidation in CD8+ T Effector Cells Is Critical for Obesity-Promoted Breast Tumor Growth. Cell Metab. 2020;31:148-161.e5 pubmed publisher |
| Renner K, Bruss C, Schnell A, Koehl G, Becker H, Fante M, et al. Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy. Cell Rep. 2019;29:135-150.e9 pubmed publisher |
| Zhou L, Mudianto T, Ma X, Riley R, Uppaluri R. Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer. Clin Cancer Res. 2019;: pubmed publisher |
| Kim T, Park G, Kim J, Lim S, Kim J, Im K, et al. CD160 serves as a negative regulator of NKT cells in acute hepatic injury. Nat Commun. 2019;10:3258 pubmed publisher |
| Fukumoto T, Fatkhutdinov N, Zundell J, Tcyganov E, Nacarelli T, Karakashev S, et al. HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer. Cancer Res. 2019;79:5482-5489 pubmed publisher |
| Chan L, Li C, Xia W, Hsu J, Lee H, Cha J, et al. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest. 2019;129:3324-3338 pubmed publisher |
| Kataru R, Ly C, Shin J, Park H, Baik J, Rehal S, et al. Tumor lymphatic function regulates tumor inflammatory and immunosuppressive microenvironments. Cancer Immunol Res. 2019;: pubmed publisher |
| Hu Q, Sun W, Wang J, Ruan H, Zhang X, Ye Y, et al. Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy. Nat Biomed Eng. 2018;2:831-840 pubmed publisher |
| Choi H, Deng J, Li S, Silk T, Dong L, Brea E, et al. Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. Cell Rep. 2019;27:806-819.e5 pubmed publisher |
| Iwata T, Ishii C, Ishida S, Ogitani Y, Wada T, Agatsuma T. A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model. Mol Cancer Ther. 2018;17:1494-1503 pubmed publisher |
| Barbet G, Sander L, Geswell M, Leonardi I, Cerutti A, Iliev I, et al. Sensing Microbial Viability through Bacterial RNA Augments T Follicular Helper Cell and Antibody Responses. Immunity. 2018;48:584-598.e5 pubmed publisher |
| Wang C, Wang J, Zhang X, Yu S, Wen D, Hu Q, et al. In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy. Sci Transl Med. 2018;10: pubmed publisher |
| Luo N, Nixon M, Gonzalez Ericsson P, Sanchez V, Opalenik S, Li H, et al. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun. 2018;9:248 pubmed publisher |
| Zhang Y, Kurupati R, Liu L, Zhou X, Zhang G, Hudaihed A, et al. Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell. 2017;32:377-391.e9 pubmed publisher |
| Saha D, Martuza R, Rabkin S. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. Cancer Cell. 2017;32:253-267.e5 pubmed publisher |
| Poon E, Mullins S, Watkins A, Williams G, Koopmann J, Di Genova G, et al. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment. J Immunother Cancer. 2017;5:63 pubmed publisher |
| Aguilera T, Rafat M, Castellini L, Shehade H, Kariolis M, Hui A, et al. Reprogramming the immunological microenvironment through radiation and targeting Axl. Nat Commun. 2016;7:13898 pubmed publisher |
| Ngiow S, Young A, Blake S, Hill G, Yagita H, Teng M, et al. Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor. Cancer Res. 2016;76:6266-6277 pubmed |
| Maute R, Gordon S, Mayer A, McCracken M, Natarajan A, Ring N, et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci U S A. 2015;112:E6506-14 pubmed publisher |
| Almishri W, Deans J, Swain M. Rapid activation and hepatic recruitment of innate-like regulatory B cells after invariant NKT cell stimulation in mice. J Hepatol. 2015;63:943-51 pubmed publisher |
| Lei G, Zhang C, Lee C. Myeloid-derived suppressor cells impair alveolar macrophages through PD-1 receptor ligation during Pneumocystis pneumonia. Infect Immun. 2015;83:572-82 pubmed publisher |
| Murakami R, Denda Nagai K, Hashimoto S, Nagai S, Hattori M, Irimura T. A unique dermal dendritic cell subset that skews the immune response toward Th2. PLoS ONE. 2013;8:e73270 pubmed publisher |
| Scarlett U, Rutkowski M, Rauwerdink A, Fields J, Escovar Fadul X, Baird J, et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med. 2012;209:495-506 pubmed publisher |
| Meng Q, Yang P, Li B, Zhou H, Huang X, Zhu L, et al. CD4+PD-1+ T cells acting as regulatory cells during the induction of anterior chamber-associated immune deviation. Invest Ophthalmol Vis Sci. 2006;47:4444-52 pubmed |
